Sector News

Eli Lilly scouts smaller deals in immunology, cancer

January 15, 2018
Life sciences

Eli Lilly has tended to stay away from megadeals, and a big influx of cash from U.S. tax reform won’t change that.

Behemoth buys are the sorts of deals Darren Carroll, SVP of corporate business development, thinks will see the biggest boost as companies bring their overseas earnings home, and “those deals, frankly, we don’t believe are very helpful for shareholders on either side of the equation.”

“Every time we look at them, they just don’t make sense,” he said in a Tuesday interview at the J.P. Morgan Healthcare Conference, adding that “what they do is distract people.”

That’s not to say Lilly won’t benefit from the new legislation. On the contrary, a reduced corporate tax rate will make Lilly “much more competitive on a deal-by-deal basis,” Carroll said, and the Indianapolis drugmaker expects to put its new tax-rate parity to good use.

For starters, it is scouting opportunities to bolster its immunology pipeline behind psoriasis newcomer Taltz and baricitinib, an arthritis product that’s won global approvals but hasn’t yet snagged the FDA’s greenlight.

And “we will, on a very selective basis, look to act” in oncology as well, Carroll said. In pain management, an area where Lilly has built its entire pipeline through deals, “we think we’re in a great position to be a partner for companies,” he added.

Lilly may also come into cash if it goes through with an animal health divestment it’s currently weighing. Last October, it said it would evaluate options for that unit, Elanco, including a potential sale or spinoff.

Make no mistake though, Carroll said: Lilly doesn’t need the money.

“This is not a business that we have to sell,” he said, adding, “We’re not in any way, shape or form looking to divest because we’ve done something else that compels us to get the cash.”

The possibility of jettisoning Elanco arose from the fact that “capital allocation now is favoring the human side of things,” but Lilly could still very well decide to keep the unit. “We’re taking a very broad look … we’ll really know by the middle of this year, and we’ll be coming back to the market and letting people know,” Carroll said.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach